US Stock MarketDetailed Quotes
AZTR Azitra
- 0.190
- -0.012-5.89%
Close May 24 16:00 ET
- 0.202
- +0.011+5.94%
Post 19:58 ET
5.48MMarket Cap-442P/E (TTM)
0.209High0.190Low416.81KVolume0.209Open0.202Pre Close81.59KTurnover2.50%Turnover RatioLossP/E (Static)28.80MShares5.18052wk High1.27P/B3.18MFloat Cap0.16152wk Low--Dividend TTM16.71MShs Float5.180Historical High--Div YieldTTM9.30%Amplitude0.161Historical Low0.195Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
Azitra Stock Forum
NEWS
Azitra Presents Preclinical Data From ATR-04 At Society Of Investigative Dermatology Annual Meeting
Benzinga· 37 mins ago1min
Azitra (AZTR.US
ATR-04 is in development for epidermal growth factor receptor inhibitor (EGFRi)-induced dermal toxicity, which affects approximately 150,000 patients in the US
Reduces methicillin-resistant S. aureus by 99% on ex vivo pig skin
Reduces IL-36g, a pro-inflammatory cytokine that drives inflammation in EGFRi-induced toxicity, in human ski...
Azitra, Inc., a company in the field of clinical-stage biopharmaceuticals dedicated to pioneering precision dermatology, is at the horizon of an exciting development in the treatment of Netherton Syndrome. On May 10, 2024, during the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in Baltimore, MD, Azitra u...
NEWS
Azitra, Inc. Announces Positive Preclinical Data of Atr-12 and Clinical Design in Netherton Syndrome Presented at the Asgct Annual Meeting
📊⚡️📊
No comment yet